风险提示：终端市场需求波动风险、海外市场风险、核心设备依赖外采风险、 在建产能建成及达产进度不及预期风险。 [Table_QuotePic] 相对指数表现 单位：百万元 2023A 2024E 2025E 2026E 3）数字化缝纫设备为 TEXPA 产品，目前处于市场开发初期，有望快速放量，同时在起量 后毛利率将快速提高。预计 2024-2026 年 TEXPA 订单同比增长 50%、20%、15%，毛利率分 别为 25%、28%、30%。 请务必阅读正文后的重要声明部分 2 请务必阅读正文后的重要声明部分 3 投资评级说明 | --- | --- | --- | --- | |----------|----------------|-------|---------------------------------------------------------------------| | | | | | | | | | | | 行业评级 | 跟随大市：未来 | 6 | 个月内，行业整体回报介于同期相关证券市场代表性指数 -5% 与 5% 之间 | | | 弱于大市：未来 | | 个月内，行业整体回报低于 ...

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 25.00 CNY over the next six months [1]. Core Insights - The company has shown significant growth in revenue and profit, with a 2023 revenue of 14.1 billion CNY, a 21.9% increase year-on-year, and a net profit of 1.6 billion CNY, recovering from a loss in the previous year [50]. - The company is positioned as a leading player in the industrial automation sector, particularly in the energy industry, benefiting from the domestic push for self-controlled systems in power generation [27][28]. - The company has a strong order pipeline, with multiple contracts secured for DCS system projects, indicating an acceleration in demand [8][50]. Financial Performance - Revenue growth is projected to continue, with expected revenues of 19.0 billion CNY in 2024 (+35.0%), 24.4 billion CNY in 2025 (+28.6%), and 30.5 billion CNY in 2026 (+24.7%) [34]. - The net profit forecast for 2024 is 2.4 billion CNY (+49.9%), followed by 3.1 billion CNY in 2025 (+29.4%) and 4.0 billion CNY in 2026 (+27.4%) [34]. - The company's EPS is expected to be 1.00 CNY in 2024, 1.30 CNY in 2025, and 1.66 CNY in 2026, with corresponding dynamic PE ratios of 16, 12, and 10 [34][68]. Business Overview - The company has over 30 years of experience in the industrial automation and information technology sectors, providing a comprehensive range of products and solutions including DCS, PLC, industrial robots, and real-time databases [4][6]. - The company has established a robust incentive mechanism to align the interests of management and shareholders, enhancing team motivation and cohesion [5]. - The company is actively expanding its international presence, with projects in countries such as Pakistan, Dubai, and Hungary, enhancing its brand influence in overseas markets [30]. Market Position - The company is recognized as a top-tier provider of DCS systems in China, with a significant market share in the power generation sector, particularly in the context of increasing domestic demand for self-controlled systems [27][28]. - The company has successfully transitioned to a fully self-controlled system, the NT6000, which has been certified by relevant authorities and implemented in major projects [55]. Future Outlook - The company is well-positioned to capitalize on the ongoing trends in industrial automation and digital transformation, with a focus on intelligent manufacturing and the integration of AI technologies [30]. - The anticipated growth in the industrial automation sector, driven by government initiatives such as "Industry 4.0" and "Made in China 2025," presents significant long-term growth opportunities for the company [30].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a revenue of 5.96 billion yuan in 2023, representing a year-on-year growth of 16.1%, and a net profit of 1.72 billion yuan, up 11.0% year-on-year. In Q4 2023, revenue was 1.52 billion yuan, with a year-on-year increase of 10.4%, and net profit was 370 million yuan, up 7.0% year-on-year. For Q1 2024, revenue reached 1.77 billion yuan, a year-on-year growth of 11.1%, and net profit was 590 million yuan, up 10.0% year-on-year, aligning with market expectations [2][3] Summary by Sections Financial Performance - In 2023, the company’s revenue from high-end, mid-range, and low-end liquor was 5.68 billion yuan (+16.6%), 80 million yuan (-19.8%), and 90 million yuan (+0.7%) respectively. Overall sales volume and price per ton increased by 7.4% and 7.6% respectively. The company plans to launch new products to enhance product structure [2][3] - For Q1 2024, the company reported a gross margin of 76.5%, with a net profit margin of 33.3%. The cash flow remains stable, with cash receipts of 1.4 billion yuan, up 15.5% year-on-year [2][3] Market and Product Strategy - The company is positioned to benefit from the upgrading of the Anhui liquor industry, with a focus on high-end products. The company aims to double sales volume and significantly increase the proportion of mid-to-high-end products in its portfolio by 2024 [2][3] - The company plans to enhance brand influence and market presence through strategic marketing and product launches, particularly focusing on the "Jian" series [2][3] Earnings Forecast - The earnings per share (EPS) for 2024-2026 are projected to be 2.87 yuan, 3.33 yuan, and 3.83 yuan respectively, with corresponding dynamic price-to-earnings (PE) ratios of 15, 13, and 11. The company is expected to maintain a high return on equity (ROE) of 18.94% in 2024 [2][3][10]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company's performance remains stable with continuous optimization of expenses [2] - Core businesses show highlights: - Respiratory therapy business revenue reached 3.37 billion yuan (+50.6%) in 2023, with key products like ventilators, oxygen concentrators, and nebulizers growing at +60%, +30%, and +60% respectively [2] - Diabetes care business revenue reached 730 million yuan (+37.1%) in 2023, with the new 14-day calibration-free CGM product CT3 expected to drive growth in 2024 [2] - Home electronics business revenue reached 1.67 billion yuan (+10.1%) in 2023, with electronic blood pressure monitors growing over 20% [2] - Infection control business revenue declined to 760 million yuan (-36.2%) in 2023 due to high base effects [2] - Emergency care business revenue reached 160 million yuan (+8.0%) in 2023, with the self-developed AED product M600 expanding globally [2] - Rehabilitation and clinical equipment business revenue declined to 1.22 billion yuan (-12.8%) in 2023, but products like wheelchairs and acupuncture needles maintained good growth [2] Financial Performance - 2023 revenue: 7.97 billion yuan (+12.3%), net profit: 2.4 billion yuan (+50.2%) [2] - 2024 Q1 revenue: 2.23 billion yuan (-17.4%), net profit: 660 million yuan (-7.6%) [2] - 2023 gross margin: 51.5% (+3.4pp), net margin: 29.8% (+7.7pp) [2] - Expense ratios in 2023: sales 13.8% (-0.7pp), management 5.2% (-0.8pp), R&D 6.3% (-0.7pp), financial -2.0% (-0.6pp) [2] Strategic Direction - The company adheres to the strategy of "Innovation Reshaping Medical Devices" and focuses on three core sectors: respiratory, POCT, and infection control [3] - The company is also developing incubation businesses (emergency, ophthalmology, rehabilitation) and cornerstone businesses (blood pressure monitoring, temperature monitoring, TCM equipment, surgical instruments) while advancing internationalization [3] Business Projections - Revenue projections for 2024-2026: 9/10.3/11.9 billion yuan [3] - Net profit projections for 2024-2026: 2.3/2.6/3.0 billion yuan [3] - PE ratios for 2024-2026: 16/14/12x [3] Key Assumptions - Respiratory oxygen supply: Expected growth of 20% annually from 2024-2026, with gross margin of 56.5% [8] - Diabetes care: Expected growth of 30% annually from 2024-2026, with gross margin increasing from 63% to 67% [8] - Infection control solutions: Expected growth of 10% annually from 2024-2026, with gross margin of 50% [8] - Home electronic testing and IVD: Expected growth of 5% annually from 2024-2026, with gross margin of 50% [8] - Rehabilitation and clinical equipment: Expected stable growth from 2024-2026, with gross margin increasing from 34% to 35% [8] - Emergency care: Expected growth of 10% annually from 2024-2026, with gross margin of 32% [8] Financial Metrics - 2023 ROE: 19.94%, expected to stabilize around 16% from 2024-2026 [4] - 2023 EPS: 2.39 yuan, expected to grow to 2.98 yuan by 2026 [4] - 2023 PB: 3.12x, expected to decline to 2.02x by 2026 [4] - 2023 dividend yield: 1.63%, expected to range between 1.28%-1.41% from 2024-2026 [12]

[Table_StockInfo] 买入 2024年 4月 26日 （维持） 证券研究报告•2023年报及2024年一季报点评 当前价： 60.44元 通策医疗（600763） 医药生物 目标价： ——元（6个月） 经营逐渐企稳，静待拐点 投资要点 西南证券研究发展中心 [T ab业le绩_S总u结mm：a公ry司] 发布 2024年一季报和 2023年年报。2024年一季度实现收入 [分Ta析bl师e_：Au杜th向or阳] 7.1亿元（+5%），归母净利润1.7亿元（+2.5%），扣非后约1.7亿元（+4.2%）。 执业证号：S1250520030002 2023年公司实现收入28.5亿元（+4.7%），归母净利润5亿元（-8.7%），扣 电话：021-68416017 非后约4.8亿元（-8.4%）。 邮箱：duxy@swsc.com.cn  23年业绩承压，24年 Q1业绩符合预期。公司2023年收入同比增长4.7%，净 分析师：王钰畅 利润增速-6.1%。24年一季度收入增速5%，净利润增速3.2%。2023年公司种 执业证号：S1250524010001 电话：021-68416017 植收入 ...

[Table_StockInfo] 买入 2024年 04月 30日 （维持） 证券研究报告•23年报及24年一季报点评 当前价： 150.43元 五 粮 液（000858） 食品饮料 目标价： ——元（6个月） 23 年稳健增长，分红比例提升 投资要点 西南证券研究发展中心 [T ab事le件_S：u公mm司a2ry0]2 3年实现收入 832.7亿元，同比+12.6%，归母净利润 302.1亿 [分Ta析bl师e_：Au朱th会or振] 元，同比+13.2%；其中 23单Q4实现收入 207.4亿元，同比+14.0%，归母净 执业证号：S1250513110001 利润 73.8亿元，同比+10.1%。此外，公司拟每10股派发现金红利46.7元（含 电话：023-63786049 税），股利支付率60%。24Q1实现收入348.3亿元，同比+11.9%，归母净利润 邮箱：zhz@swsc.com.cn 140.5亿元，同比+12.0%，24Q1收入和利润符合市场预期。 分析师：王书龙  23年圆满完成增长目标，24Q1顺利实现开门红。1、分产品，23年五粮液产 品实现收入 628.0 亿元，同比+13 ...

Investment Rating - The report maintains a "Buy" rating for Xinhua Winshare (601811) [1] Core Views - Xinhua Winshare achieved a 2023 operating income of 11.87 billion yuan, up 8.6% YoY, with net profit attributable to shareholders of 1.58 billion yuan, up 13.1% YoY [1] - In Q1 2024, the company reported revenue of 2.47 billion yuan, up 7% YoY, but net profit attributable to shareholders decreased by 3.3% to 210 million yuan [1] - The company has a stable dividend policy, with a 2023 dividend yield of 5.2% for its H-shares [2] - The company is expected to benefit from the Western Development Strategy, potentially qualifying for a 15% corporate income tax rate [8] Business Performance Publishing Business - In 2023, the publishing business generated revenue of 2.99 billion yuan, up 8.8% YoY [42] - In Q1 2024, the publishing business achieved revenue of 890 million yuan, with 550 million yuan from textbooks and 250 million yuan from general books [42] - The company ranks 11th in market share among 37 publishing groups in China and 7th among local publishing groups [42] Distribution Business - In 2023, the distribution business achieved revenue of 10.49 billion yuan, up 5.5% YoY [19] - In Q1 2024, the distribution business generated revenue of 2.17 billion yuan, with 1.14 billion yuan from textbooks and 960 million yuan from general books [19] - The company is actively expanding into short video and live streaming e-commerce channels, with expected growth rates of 30%/25%/20% for 2024-2026 [7] Education Informatization - The company is focusing on education informatization, covering 6,190 schools and serving 4.662 million students through its "Wenxuan Youxue" online platform [19] Financial Forecasts - Revenue is expected to grow from 11.87 billion yuan in 2023 to 17.03 billion yuan in 2026, with a CAGR of 12.7% [9] - Net profit attributable to shareholders is forecasted to increase from 1.58 billion yuan in 2023 to 2.04 billion yuan in 2026 [21] - EPS is projected to rise from 1.28 yuan in 2023 to 1.65 yuan in 2026 [21] - The company's ROE is expected to remain stable at around 12% from 2023 to 2026 [21] Valuation - The company's PE ratio is forecasted to decrease from 11.45x in 2024 to 8.85x in 2026 [21] - The PB ratio is expected to decline from 1.38x in 2024 to 1.01x in 2026 [21]

Investment Rating - The report maintains a "Buy" rating for the company [1][4]. Core Views - The company reported Q1 2024 revenue of 1.86 billion yuan, a year-on-year increase of 24%, but a quarter-on-quarter decrease of 21.5%. The net profit attributable to the parent company was 210 million yuan, up 21.9% year-on-year but down 29.2% quarter-on-quarter [3]. - The company's gross margin was under pressure in Q1 2024, with a gross margin of 20.8%, down 0.7 percentage points year-on-year and 2.2 percentage points quarter-on-quarter. The net profit margin was 11.3%, down 0.4 percentage points year-on-year and 1.5 percentage points quarter-on-quarter. However, it is expected that gross margins will stabilize and recover as new projects ramp up and capacity utilization improves [3]. - The company is expanding its lightweight production capacity, with the first phase of a project in Mexico producing 4 million lightweight components annually, which commenced production at the end of Q3 2023. The second phase is expected to start production by the end of 2024. Additionally, the company has added 106 new projects in Q1 2024, including a lightweight project for a North American new energy vehicle company, projected to generate approximately 1.22 billion USD in total sales over five years [3]. - The company has accelerated its layout in the automotive steer-by-wire sector, with significant progress in the development of various steering systems. The sales volume of mechanical steering products increased by 54% year-on-year in Q1 2024 [3]. Summary by Sections Financial Performance - Q1 2024 revenue: 1.86 billion yuan, +24% YoY, -21.5% QoQ - Q1 2024 net profit: 210 million yuan, +21.9% YoY, -29.2% QoQ - Q1 2024 gross margin: 20.8%, -0.7pp YoY, -2.2pp QoQ - Q1 2024 net profit margin: 11.3%, -0.4pp YoY, -1.5pp QoQ [3][4]. Growth Projections - Expected EPS for 2024-2026: 2.61, 3.34, 4.21 yuan, with corresponding PE ratios of 22, 17, and 14 times. The CAGR for net profit attributable to the parent company is projected at 26.9% [4][5]. Capacity Expansion - The company is expanding its lightweight production capacity, with significant projects in Mexico and domestic production bases. The first phase in Mexico has commenced production, and the second phase is on track for late 2024 [3]. - New projects include a lightweight project for a North American new energy vehicle company and a platform project for a German joint venture, with significant projected sales [3]. Strategic Developments - The company has made strides in the steer-by-wire sector, with a focus on integrating control systems for various automotive applications. The sales of mechanical steering products have seen substantial growth [3].

Investment Rating - The report assigns a "Hold" rating for the company, indicating a moderate outlook for the next six months [12][28][55]. Core Insights - The company is a leading player in the CNC machine tool industry, focusing on high-end intelligent equipment with a diverse range of CNC machine products [6][19][40]. - The company's performance has been under pressure in recent years, but there has been a marginal improvement since Q4 2023, driven by a recovery in the 3C consumer electronics sector [9][41][43]. - The report highlights a significant increase in overseas revenue, which grew by 74.8% year-on-year, while domestic revenue decreased by 23.9% [12][41]. - The company is expected to benefit from a new replenishment cycle in the CNC machine tool demand as the industrial inventory phase-out nears its end [28][48]. Summary by Sections 1. Company Overview - The company specializes in high-end intelligent equipment, offering a wide range of CNC machine tools applicable in various sectors including 3C electronics, 5G communications, and aerospace [6][40]. - The company has faced challenges in recent years, with a reported revenue of 3.53 billion yuan in 2023, a decrease of 22.0% year-on-year, and a net profit of 190 million yuan, down 42.0% [12][41]. 2. Financial Performance - In Q4 2023, the company achieved a revenue of 740 million yuan, marking a 15.1% increase year-on-year and a 1.7% increase quarter-on-quarter, with a net profit of 30 million yuan [12][41]. - The overall gross margin for 2023 was 23.3%, a decline of 3.3 percentage points from the previous year, while the net profit margin was 5.8%, down 1.6 percentage points [12][43]. - The company maintained a stable expense ratio of 17.8% in 2023, with a slight increase in R&D expenses supporting product upgrades [11][12]. 3. Earnings Forecast and Valuation - The report forecasts the company's net profit to reach 380 million yuan, 470 million yuan, and 580 million yuan for 2024, 2025, and 2026 respectively, indicating a compound annual growth rate of 44% [12][28]. - The expected gross margins for the CNC machine tool business are projected to improve to 24% in 2024, 24.5% in 2025, and 25% in 2026 [28][29]. - The report compares the company with peers in the CNC machine tool industry, suggesting a favorable growth outlook due to its leading position and diversified product offerings [28][30].

[Table_StockInfo] 买入 2024年 04月 30日 （维持） 证券研究报告•2024年一季报点评 当前价： 28.80元 海尔智家（600690） 家用电器 目标价： ——元（6个月） 海内外稳健增长，盈利能力加速提升 投资要点 西南证券研究发展中心 [T a事ble件_S：u公mm司a发ry布] 2024年一季报，2024年一季度公司实现营收 689.8亿元，同 [分Ta析bl师e_：Au龚th梦or泓] 比增长 6%；实现归母净利润 47.7亿元，同比增长 20.2%；实现扣非后归母净 执业证号：S1250518090001 利润46.4亿元，同比增长25.4%。 电话：023-63786049 邮箱：gmh@swsc.com.cn  海内外收入稳健增长。公司在中国市场收入增长 8.1%，其中：①制冷、洗护产 业保持稳健增长、水产业实现两位数增长；②家用空调、厨电、智慧楼宇等潜 联系人：方建钊 力产业收入增长均超 10%。卡萨帝品牌一季度收入增长14%。随着数字化转型 电话：18428374714 邮箱：fjz@swsc.com.cn 的不断深入，中国市场经营利润增长超过 30%。在 ...